The treatment — known as OMO-103 — works by suppressing MYC, which orchestrates messages telling a cell to divide.
In a study of a dozen patients with various forms of hard to treat cancer, the drug was able to halt tumor growth in eight patients. The Daily Mail
See also:
- Omomyc as the first MYC-targeted therapy to successfully complete a phase I clinical trial Vall D'Hebron Institute of Oncology
No comments:
Post a Comment